Logo image of PTN

PALATIN TECHNOLOGIES INC (PTN) Stock Fundamental Analysis

NYSEARCA:PTN - NYSE Arca - US6960775020 - Common Stock - Currency: USD

0.0941  -0.08 (-44.65%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to PTN. PTN was compared to 559 industry peers in the Biotechnology industry. PTN has a bad profitability rating. Also its financial health evaluation is rather negative. PTN is not valued too expensively and it also shows a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year PTN has reported negative net income.
PTN had a negative operating cash flow in the past year.
In the past 5 years PTN always reported negative net income.
PTN had negative operating cash flow in 4 of the past 5 years.
PTN Yearly Net Income VS EBIT VS OCF VS FCFPTN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

1.2 Ratios

With a Return On Assets value of -625.34%, PTN is not doing good in the industry: 97.15% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -625.34%
ROE N/A
ROIC N/A
ROA(3y)-176.98%
ROA(5y)-121.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PTN Yearly ROA, ROE, ROICPTN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K -10K 20K -20K

1.3 Margins

The Gross Margin of PTN (1255.00%) is better than 100.00% of its industry peers.
In the last couple of years the Gross Margin of PTN has declined.
The Profit Margin and Operating Margin are not available for PTN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 1255%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.23%
GM growth 5YN/A
PTN Yearly Profit, Operating, Gross MarginsPTN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10K -10K

More info and screens

0

2. Health

2.1 Basic Checks

PTN does not have a ROIC to compare to the WACC, probably because it is not profitable.
PTN has more shares outstanding than it did 1 year ago.
The number of shares outstanding for PTN has been increased compared to 5 years ago.
The debt/assets ratio for PTN has been reduced compared to a year ago.
PTN Yearly Shares OutstandingPTN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
PTN Yearly Total Debt VS Total AssetsPTN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

PTN has an Altman-Z score of -171.53. This is a bad value and indicates that PTN is not financially healthy and even has some risk of bankruptcy.
PTN's Altman-Z score of -171.53 is on the low side compared to the rest of the industry. PTN is outperformed by 98.22% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -171.53
ROIC/WACCN/A
WACC10.35%
PTN Yearly LT Debt VS Equity VS FCFPTN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 0.38 indicates that PTN may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.38, PTN is doing worse than 94.48% of the companies in the same industry.
A Quick Ratio of 0.38 indicates that PTN may have some problems paying its short term obligations.
With a Quick ratio value of 0.38, PTN is not doing good in the industry: 94.13% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.38
Quick Ratio 0.38
PTN Yearly Current Assets VS Current LiabilitesPTN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 40.31% over the past year.
PTN shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -95.07%.
Measured over the past years, PTN shows a very negative growth in Revenue. The Revenue has been decreasing by -40.52% on average per year.
EPS 1Y (TTM)40.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.57%
Revenue 1Y (TTM)-95.07%
Revenue growth 3YN/A
Revenue growth 5Y-40.52%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, PTN will show a very strong growth in Earnings Per Share. The EPS will grow by 30.24% on average per year.
The Revenue is expected to grow by 162.67% on average over the next years. This is a very strong growth
EPS Next Y51.7%
EPS Next 2Y52.7%
EPS Next 3Y48.26%
EPS Next 5Y30.24%
Revenue Next Year-100%
Revenue Next 2Y325.2%
Revenue Next 3Y164.44%
Revenue Next 5Y162.67%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PTN Yearly Revenue VS EstimatesPTN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2017 2018 2019 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 0 100M 200M 300M 400M 500M
PTN Yearly EPS VS EstimatesPTN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 -4 -6

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

PTN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Based on the Price/Forward Earnings ratio of 0.14, the valuation of PTN can be described as very cheap.
99.64% of the companies in the same industry are more expensive than PTN, based on the Price/Forward Earnings ratio.
PTN is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.39, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 0.14
PTN Price Earnings VS Forward Price EarningsPTN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PTN Per share dataPTN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as PTN's earnings are expected to grow with 48.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y52.7%
EPS Next 3Y48.26%

More info and screens

0

5. Dividend

5.1 Amount

PTN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PALATIN TECHNOLOGIES INC

NYSEARCA:PTN (5/7/2025, 8:04:01 PM)

0.0941

-0.08 (-44.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13 2025-02-13/bmo
Earnings (Next)05-20 2025-05-20/bmo
Inst Owners14.18%
Inst Owner Change14.18%
Ins Owners0.72%
Ins Owner Change6.19%
Market Cap2.45M
Analysts80
Price Target7.14 (7487.67%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)48%
Min EPS beat(2)24.29%
Max EPS beat(2)71.71%
EPS beat(4)3
Avg EPS beat(4)25.29%
Min EPS beat(4)-5.65%
Max EPS beat(4)71.71%
EPS beat(8)3
Avg EPS beat(8)-26.04%
EPS beat(12)6
Avg EPS beat(12)-12.52%
EPS beat(16)8
Avg EPS beat(16)-16.16%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-58.82%
EPS NQ rev (1m)0%
EPS NQ rev (3m)63.04%
EPS NY rev (1m)0%
EPS NY rev (3m)40.36%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.14
P/S 6.99
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.54
EYN/A
EPS(NY)0.69
Fwd EY729.86%
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1.04
OCFYN/A
SpS0.01
BVpS-0.25
TBVpS-0.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -625.34%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 1255%
FCFM N/A
ROA(3y)-176.98%
ROA(5y)-121.45%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-18.23%
GM growth 5YN/A
F-Score3
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 1.53%
Cap/Sales 1.4%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.38
Quick Ratio 0.38
Altman-Z -171.53
F-Score3
WACC10.35%
ROIC/WACCN/A
Cap/Depr(3y)120.27%
Cap/Depr(5y)96.16%
Cap/Sales(3y)9.17%
Cap/Sales(5y)16.55%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)40.31%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%78.57%
EPS Next Y51.7%
EPS Next 2Y52.7%
EPS Next 3Y48.26%
EPS Next 5Y30.24%
Revenue 1Y (TTM)-95.07%
Revenue growth 3YN/A
Revenue growth 5Y-40.52%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y325.2%
Revenue Next 3Y164.44%
Revenue Next 5Y162.67%
EBIT growth 1Y1.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year27.47%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y22.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.15%
OCF growth 3YN/A
OCF growth 5YN/A